Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So....who is behind Oncologie?!
Oncologie - founded end of 2017!
"hot" and "cold" tumors - didn´t we have that some months ago with PPHM?
From 01/22/2018 - Mologen AG
MOLOGEN Presented Lefitolimod TME Data at ASCO GI 2018
The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) presented data on its lead compound, the TLR9 agonist and immune surveillance reactivator lefitolimod, at the Annual 2018 Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco (18 - 20 January 2018). Monotherapy with lefitolimod resulted in a beneficial modulation of the tumor microenvironment (TME) associated with a reduced tumor growth in a murine model of colorectal cancer. The beneficial lefitolimod-induced modulation of the TME strongly supports its potential as cancer immunotherapeutic agent. Hence, in addition to its potential in monotherapy, lefitolimod may also be an ideal partner for immuno-oncology combination approaches, i.e. with checkpoint inhibitors.
"Beneficial modulation of the TME, in other words making immunologically “cold” tumors “hot”, is a crucial requirement for the response to immunotherapeutic approaches. The presented data clearly support the mode-of-action of lefitolimod in our late-stage IMPALA study with single-agent lefitolimod in colorectal cancer. In addition they provide an excellent rationale for combining lefitolimod with checkpoint inhibitors. We know that checkpoint inhibitors need help to fully unfold their enormous potential and we believe that our TLR9 agonist lefitolimod will play a major role also in this context", said Dr Matthias Baumann, CMO of MOLOGEN AG.
Beneficial lefitolimod-induced modulation of the TME
After intratumoral injection of lefitolimod an increased infiltration of T cells (CD3+ T cells, especially CD8+ T cells) into the tumor was observed. Furthermore, also an increase of activated CD8+ T cells with cytolytic ("cell destruction capability") potential was determined. In addition, the injection of lefitolimod had a positive impact regarding so-called tumor-associated macrophages - immune cells that interact with tumor cells to influence the initiation, growth and metastasis of tumors. Lefitolimod led to an increase of anti-tumor M1-type macrophages within the tumor, accompanied with a decrease of pro-tumorigenic M2-type macrophages.
Importantly, this beneficial TME modulation from an immunosuppressed (“cold”) towards a more immunoreactive (“hot”) stage translated into a reduction of tumor growth in the mice.
Lefitolimod as a partner for immuno-oncological combination therapies
The lefitolimod-induced pathway provides the rationale for combining lefitolimod with checkpoint inhibitors. Response rates to checkpoint inhibitor immunotherapy vary between different tumor entities and depend on the nature of the TME. “Hot” tumors with a T cell infiltrated TME show better responses. Therefore modulation of the TME is a crucial requirement for the response to immunotherapeutic approaches.
First combination data of lefitolimod with checkpoint inhibitors have been presented at the ASCO GI 2017. The data showed that lefitolimod can significantly improve the anti-tumor effect of checkpoint inhibitors, particularly anti-PD-1 and anti-PD-L1 antibodies, and thus prolong survival in murine tumor models.
For more information on ASCO GI please visit the website:
https://gicasym.org/
(http://cts.businesswire.com/ct/CT...)
now back to CDMO
Genau:
Bavi - PS - BB - Biomarker - Liquid biopsy und so weiter .....
It is again: Dr. Laura Benjamin, Chiel Executeive Officer ONCOLOGIE
German Version:
MOLOGEN unterzeichnet Lizenzvertrag mit ONCOLOGIE für China und weltweite Entwicklungskooperation für den Hauptwirkstoffkandidaten Lefitolimod - EQS Group
13-Feb-2018 16:17:55
============
DGAP-News: MOLOGEN AG / Schlagwort(e): Vertrag/Vereinbarung
MOLOGEN unterzeichnet Lizenzvertrag mit ONCOLOGIE für China und weltweite
Entwicklungskooperation für den Hauptwirkstoffkandidaten Lefitolimod
13.02.2018 / 16:17
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
--------------------------------------------------------------------------
Pressemitteilung N 3 / 2018 vom 13.02.2018
MOLOGEN unterzeichnet Lizenzvertrag mit ONCOLOGIE für China und weltweite
Entwicklungskooperation für den Hauptwirkstoffkandidaten Lefitolimod
• MOLOGEN erhält erste Zahlung in Höhe von 3 Mio. EUR sowie eine Kapitaleinlage in Höhe von 2 Mio. EUR
• Meilensteinzahlungen von über 100 Mio. EUR und zweistellige Lizenzgebühren auf die im Markt erzielten Nettoumsätze
• Starke Unterstützung des weltweiten Entwicklungsprogramms für Lefitolimod, insbesondere in China und anderen asiatischen Regionen
Berlin, 13. Februar 2018 - Das biopharmazeutische Unternehmen MOLOGEN AG
(ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) hat
heute die Unterzeichnung eines Lizenzvertrags für China sowie eine
weltweite Entwicklungskooperation für den Hauptwirkstoffkandidaten
Lefitolimod zwischen MOLOGEN und ONCOLOGIE Inc. bekannt gegeben. Die
unterschriebene Vereinbarung ist an die Bedingung geknüpft, dass MOLOGEN
eine erste Zahlung in Höhe von 3 Mio. EUR erhält. ONCOLOGIE ist ein auf
Krebstherapien spezialisierter Medikamentenentwickler mit Hauptsitz in
Boston und operativem Standort in Shanghai. Das Unternehmen wird von
internationalen Top-Investoren unterstützt und hat die Entwicklung von
neuartigen personalisierten Arzneimitteln im Bereich der Immuno-Onkologie
zum Ziel. Der unterzeichnete Vertrag mit ONCOLOGIE beinhaltet die
Entwicklung, Produktion und Vermarktung von Lefitolimod in China sowie ein
geplantes weltweites gemeinsames Entwicklungsprogramm.
"Wir freuen uns über die Lizenzvereinbarung mit ONCOLOGIE für unseren
Hauptwirkstoffkandidaten Lefitolimod. ONCOLOGIEs Ansatz einer innovativen
Biomarker-basierten Entwicklungsstrategie für neuartige
Krebsimmuntherapien hat uns überzeugt, dass diese Partnerschaft zur
weiteren Steigerung der Erfolgsaussichten von Lefitolimod beitragen wird.
Mit der Lizenzvereinbarung und der Entwicklungskooperation für unseren
Hauptproduktkandidaten Lefitolimod haben wir einen der wichtigsten
Meilensteine bei der Umsetzung unserer Strategie erreicht. Mit ONCOLOGIE
haben wir einen Partner mit einem hoch engagierten und erfahrenen
internationalen Team gewonnen, das nicht nur die Entwicklung von
Lefitolimod bis zum Erreichen der Marktzulassung in China vorantreiben,
sondern auch unsere weltweite Entwicklung unterstützen wird. Gemeinsam
werden wir das Ziel verfolgen, Lefitolimods volles Marktpotential in China
und auf globaler Ebene auszuschöpfen", sagte Dr. Mariola Söhngen,
Vorstandsvorsitzende von MOLOGEN.
"Wir freuen uns über die Lizenzvereinbarung mit MOLOGEN zu Lefitolimod,
einem "Best-in-Class" TLR9-Agonisten mit großem Potential. Das Programm
ergänzt ONCOLOGIEs Strategie der globalen Biomarker-basierten Entwicklung
und bietet zahlreiche Behandlungsansätze für im asiatischen Markt
vorherrschende Indikationen", sagte Dr. Laura Benjamin, Chief Executive
Officer (CEO) von ONCOLOGIE.
Wie bereits angekündigt, hatte MOLOGEN Verhandlungen über einen derartigen
Vertrag mit der chinesischen iPharma geführt. Nach Ablauf der vereinbarten
Exklusivitätsperiode hat MOLOGEN den Lizensierungsprozess für weitere
interessierte Parteien wieder geöffnet. Die Abstimmungen und Verhandlungen
mit ONCOLOGIE wurden nun erfolgreich beendet und ein entsprechender
Vertrag konnte abgeschlossen werden. Die Vertragsbedingungen der
unterzeichneten Vereinbarung mit ONCOLOGIE beschreiben die Entwicklung,
Produktion und Vermarktung von Lefitolimod in China sowie eine geplante
globale Entwicklungskooperation.
Der Vertrag umfasst zwei Teile: Erstens eine Lizenzvereinbarung inklusive
der Rechte an Unterlizenzen, in der MOLOGEN ONCOLOGIE eine exklusive
Lizenz für die Entwicklung, Produktion und Vermarktung des
Hauptproduktkandidaten Lefitolimod in den Märkten China inklusive Hong
Kong und Macao, Taiwan und Singapur (Lizenzgebiet) erteilt. Zweitens eine
Vereinbarung über eine weltweite Entwicklungskooperation, welche die
innovativen Biomarker-Pläne von ONCOLOGIE nutzt. MOLOGEN erhält von
ONCOLOGIE eine erste Zahlung in Höhe von 3 Mio. EUR sowie innerhalb der
kommenden 12 Monate eine Kapitaleinlage in Höhe von 2 Mio. EUR. Neben der
initialen Zahlung und der Kapitaleinlage, haben sich die beiden Parteien
auf weitere Entwicklungs- und Vermarktungsmeilensteine geeinigt. Diese
sind fällig, sobald die vordefinierten Entwicklungsschritte bzw. die
Marktzulassung erreicht wurden. Außerdem werden kommerzielle Meilensteine
definiert, die bei Erreichen bestimmter Umsatzschwellen fällig werden. Die
Gesamthöhe der Zahlungen kann eine Größenordnung von mehr als 100 Mio. EUR
erreichen und diese werden über mehrere Jahre hinweg geleistet.
Darüber hinaus wird MOLOGEN niedrige zweistellige Lizenzgebühren auf die
im Markt erzielten Umsätze erhalten. MOLOGEN und ONCOLOGIE werden sich die
erzielten Gewinne aus der weltweiten Entwicklungskooperation entsprechend
ihres jeweiligen Beitrags teilen. ONCOLOGIE übernimmt alle mit der
Entwicklung, Registrierung, dem Vertrieb und der Vermarktung von
Lefitolimod verbundenen Kosten in den vertraglich definierten Märkten.
ONCOLOGIE Inc.
ONCOLOGIE ist ein Krebstherapie-Unternehmen, das auf der Basis innovativer
Wirkstoffkandidaten und einer Biomarker-basierten klinischen Entwicklung
bessere Ergebnisse für Krebspatienten liefern möchte. Die aktuelle
Pipeline legt den Schwerpunkt auf klinische Programme im mittleren
Entwicklungsstadium, die die Mikroumgebung des Tumors verändern. Mit
Hauptsitz in Boston, Massachusetts, USA, und operativem Standort in
Shanghai, China, arbeitet ONCOLOGIE weltweit mit Partnern zusammen, um
innovative Medikamente für Krebspatienten auf der ganzen Welt zu erwerben
und zu entwickeln.
www.oncologie.international
MOLOGEN AG
MOLOGEN AG ist ein biopharmazeutisches Unternehmen, das mit einzigartigen
Technologien und Wirkstoffen zu den Wegbereitern auf dem Gebiet der
Immuntherapien gehört. Neben dem Schwerpunkt Immuno-Onkologie entwickelt
MOLOGEN zudem Immuntherapien zur Behandlung von Infektionskrankheiten.
Das Immuntherapeutikum Lefitolimod (MGN1703) ist das
Hauptentwicklungsprodukt des Unternehmens und wird als "Best-in-Class"
TLR9-Agonist angesehen. Die Behandlung mit Lefitolimod führt zu einer
breiten und starken Aktivierung des Immunsystems. Aufgrund dieses
Wirkmechanismus gilt Lefitolimod als Immune Surveillance Reactivator (ISR)
und besitzt das Potenzial, in verschiedenen Indikationen eingesetzt zu
werden. Der ISR Lefitolimod wird zurzeit im Rahmen einer pivotalen Studie
für die Erstlinien-Erhaltungstherapie bei Darmkrebs entwickelt.
Wesentliche Daten der Phase-II-Studie IMPULSE in kleinzelligem Lungenkrebs
wurden im April 2017 bekannt gegeben. Derzeit erfolgen detaillierte
Auswertungen der IMPULSE-Daten sowie der Daten der Erweiterungsphase der
TEACH-Studie in HIV, die im August 2017 veröffentlicht wurden. Zudem wird
Lefitolimod derzeit in einer Phase-I-Kombinationsstudie mit dem Checkpoint
Inhibitor Ipilimumab (Yervoy^(R)) in verschiedenen Krebserkrankungen
untersucht. Neben verschiedenen Checkpoint Inhibitoren ist Lefitolimod,
das sich in einer klinischen Studie Phase III befindet, einer der wenigen
marktnahen Produktkandidaten im Bereich der Immuno-Onkologie.
Die Pipeline von MOLOGEN steht für neue innovative Immuntherapien,
insbesondere zum Einsatz gegen Krankheiten, für die ein hoher
medizinischer Bedarf besteht.
www.mologen.com
Kontakt
Claudia Nickolaus
Leiterin Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com
Risikohinweis zu den Zukunftsaussagen
Bestimmte Angaben in dieser Meldung beinhalten zukunftsgerichtete
Ausdrücke oder die entsprechenden Ausdrücke mit Verneinung oder hiervon
abweichende Versionen oder vergleichbare Terminologien, diese werden als
zukunftsgerichtete Aussagen (forward-looking statements) bezeichnet.
Zusätzlich beinhalten sämtliche hier gegebenen Informationen, die sich auf
geplante oder zukünftige Ergebnisse von Geschäftsbereichen,
Finanzkennzahlen, Entwicklungen der finanziellen Situation oder andere
Finanzzahlen oder statistische Angaben beziehen, solche in die Zukunft
gerichtete Aussagen. Das Unternehmen weist vorausschauende Investoren
darauf hin, sich nicht auf diese Zukunftsaussagen als Vorhersagen über die
tatsächlichen zukünftigen Ereignisse zu verlassen. Das Unternehmen
verpflichtet sich nicht, und lehnt jegliche Haftung dafür ab, in die
Zukunft gerichtete Aussagen zu aktualisieren, die nur den Stand am Tage
der Veröffentlichung wiedergeben.
--------------------------------------------------------------------------
13.02.2018 Veröffentlichung einer Corporate News/Finanznachricht,
übermittelt durch DGAP - ein Service der EQS Group AG.
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber
verantwortlich.
Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten,
Corporate News/Finanznachrichten und Pressemitteilungen.
Medienarchiv unter http://www.dgap.de
--------------------------------------------------------------------------
Sprache: Deutsch
Unternehmen: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Deutschland
Telefon: 030 / 841788-0
Fax: 030 / 841788-50
E-Mail: presse@mologen.com
Internet: www.mologen.com
ISIN: DE0006637200
WKN: 663720
Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
Börsen: in Berlin, Düsseldorf, Hamburg, München, Stuttgart, Tradegate
Exchange
Ende der Mitteilung DGAP News-Service
653947 13.02.2018
1 fncls.ssp?fn=show_t_gif&application_id=653947&application_name=news&site_id=reuters8
References
Visible links
Mologen AG - in Germany - up 25%
Dart .... maybe
and the old Crew... maybe
and the new Crew... maybe
There is something going on IMO
That is no coincidence!!! IMO
There is somethoing going on--- Oncologie.....IMO
Mologen AG - MOLOGEN signs license deal for China and global co-development agreement with ONCOLOGIE for lead compound lefitolimod - PUBT
13-Feb-2018 16:18
The Executive Board of biopharmaceutical company MOLOGEN AG (ISIN DE0006637200, SIN 663720) today announced the signing of a license deal for the Chinese territory and a global co-development agreement between MOLOGEN and ONCOLOGIE Inc. for its lead compound lefitolimod. The signed agreement is conditional upon an initial payment of EUR 3 million received by MOLOGEN. ONCOLOGIE is an
(http://www.mologen.com/en/investor-relations-press/news/ad-hoc-news/20...) -focused drug development company with headquarters in Boston, US, and operations in Shanghai. The company is backed by top-tier international investors and has the objective to develop novel personalized medicines in the field of immuno-
(http://www.mologen.com/en/investor-relations-press/news/ad-hoc-news/20...). The signed agreement with ONCOLOGIE includes the development, manufacture and commercialization of lefitolimod in China and a planned global co-development program.
As previously announced, MOLOGEN had started negotiations on such a deal with the Chinese iPharma. After a certain exclusivity period had expired, MOLOGEN opened the licencing process also for additional parties. Discussions and negotiations with ONCOLOGIE have now been successfully completed and the deal could be signed. The terms of the signed agreement with ONCOLOGIE define development, manufacture and commercialization of lefitolimod in China and a planned global co-development program.
The contract comprises two parts: First, a license agreement including sublicense rights under which MOLOGEN grants ONCOLOGIE an exclusive license for the development, manufacturing and commercialization for MOLOGEN's lead compound lefitolimod in the following territory: China, Hong Kong and Macao, Taiwan and Singapore. Second, a commitment for global co-development leveraging novel biomarker plans from ONCOLOGIE. MOLOGEN is to receive an initial payment of EUR 3 million as well as a EUR 2 million equity investment by ONCOLOGIE within the next 12 months.
Besides the initial payment and the equity investment, the parties agreed on further development and commercialisation milestones. They are due upon reaching predefined development steps as well as market approval. In addition, commercial milestones are defined which are due upon reaching certain sales thresholds. The total payments can amount to above EUR 100 million and will be paid over several years. Additionally, MOLOGEN will receive low double digit royalties on sales. MOLOGEN and ONCOLOGIE will share the economic returns from global joint development pursuant to both parties' contributions.
All costs relating to development, registration, marketing and commercialization of lefitolimod in the territory are to be covered by ONCOLOGIE.
Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com
Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.
Attachments
* Original document
(http://www.mologen.com/en/investor-relations-press/news/ad-hoc-news/20...)
Discalimer
Mologen AG published this content on 13 February 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 13 February 2018 15:18:20 UTC
(C) Copyright 2018 - Mologen AG
Is this "our" ONCOLOGIE???
MOLOGEN signs license deal for China and global co-development agreement with ONCOLOGIE for lead compound lefitolimod - EQS
13-Feb-2018 16:11
============
DGAP-Ad-hoc: MOLOGEN AG / Key word(s): Contract/Agreement
MOLOGEN signs license deal for China and global co-development agreement
with ONCOLOGIE for lead compound lefitolimod
13-Feb-2018 / 16:11 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by
DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
--------------------------------------------------------------------------
Publication of an insider information pursuant to Section 17 of the
regulation (EU) No. 596/2014
MOLOGEN signs license deal for China and global co-development agreement
with ONCOLOGIE for lead compound lefitolimod
Berlin, 13 February 2018 - The Executive Board of biopharmaceutical
company MOLOGEN AG (ISIN DE0006637200, SIN 663720) today announced the
signing of a license deal for the Chinese territory and a global
co-development agreement between MOLOGEN and ONCOLOGIE Inc. for its lead
compound lefitolimod. The signed agreement is conditional upon an initial
payment of EUR 3 million received by MOLOGEN. ONCOLOGIE is an
oncology-focused drug development company with headquarters in Boston, US,
and operations in Shanghai. The company is backed by top-tier
international investors and has the objective to develop novel
personalized medicines in the field of immuno-oncology. The signed
agreement with ONCOLOGIE includes the development, manufacture and
commercialization of lefitolimod in China and a planned global
co-development program.
As previously announced, MOLOGEN had started negotiations on such a deal
with the Chinese iPharma. After a certain exclusivity period had expired,
MOLOGEN opened the licencing process also for additional parties.
Discussions and negotiations with ONCOLOGIE have now been successfully
completed and the deal could be signed. The terms of the signed agreement
with ONCOLOGIE define development, manufacture and commercialization of
lefitolimod in China and a planned global co-development program.
The contract comprises two parts: First, a license agreement including
sublicense rights under which MOLOGEN grants ONCOLOGIE an exclusive
license for the development, manufacturing and commercialization for
MOLOGEN's lead compound lefitolimod in the following territory: China,
Hong Kong and Macao, Taiwan and Singapore. Second, a commitment for global
co-development leveraging novel biomarker plans from ONCOLOGIE. MOLOGEN is
to receive an initial payment of EUR 3 million as well as a EUR 2 million
equity investment by ONCOLOGIE within the next 12 months.
Besides the initial payment and the equity investment, the parties agreed
on further development and commercialisation milestones. They are due upon
reaching predefined development steps as well as market approval. In
addition, commercial milestones are defined which are due upon reaching
certain sales thresholds. The total payments can amount to above EUR 100
million and will be paid over several years. Additionally, MOLOGEN will
receive low double digit royalties on sales. MOLOGEN and ONCOLOGIE will
share the economic returns from global joint development pursuant to both
parties' contributions.
All costs relating to development, registration, marketing and
commercialization of lefitolimod in the territory are to be covered by
ONCOLOGIE.
- End of the ad-hoc notification -
Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
1 investor@mologen.com
Note about risk for future predictions
Certain information in this report contains forward-looking statements or
the corresponding statements with negation or versions deviating from this
or comparable terminology. These are described as forward-looking
statements. In addition, all of the information given here that refers to
planned or future results of business areas, key financial figures,
developments of the financial situation or other financial figures or
statistical data, is to be understood as such forward-looking statements.
The company points out to investors that they should not rely on these
forward-looking statements as predictions about actual future events. The
company is not obligated and refuses to accept any liability for the
forward-looking statements and has no obligation to update such statements
in order to accurately reflect the current situation.
--------------------------------------------------------------------------
13-Feb-2018 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
--------------------------------------------------------------------------
Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Germany
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: presse@mologen.com
Internet: www.mologen.com
ISIN: DE0006637200
WKN: 663720
Regulated Market in Frankfurt (Prime Standard); Regulated
Listed: Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange
End of Announcement DGAP News Service
653935 13-Feb-2018 CET/CEST
2 fncls.ssp?fn=show_t_gif&application_id=653935&application_name=news&site_id=reuters8
References
Visible links
1. mailto:investor@mologen.com
Just ask her.....
Laura E. Benjamin, Ph.D.
Associate Professor of Pathology
Associate Director, CVBR
Beth Israel Deaconess Medical Center
Harvard Medical School
330 Brookline Avenue, RN227D
Boston, MA 02215
Office: 617-667-5964
Fax: 617-667-3616
Email:
lbenjami@bidmc.harvard.edu
http://cvbr.hms.harvard.edu/researchers/benjamin.html
Bavi gone with the wind
This Lady?
Laura E. Benjamin, Ph.D.
http://cvbr.hms.harvard.edu/researchers/benjamin.html
Liquid biopsy' promises early detection for cancer
By Jocelyn KaiserJan. 18, 2018 , 2:00 PM
The Johns Hopkins researchers and collaborators found.......
"That's a very attractive number," says molecular pathologist Anirban Maitra of the MD Anderson Cancer Center in Houston, Texas, because it is in the range of other cancer screening tests such as colonoscopy..........
http://www.sciencemag.org/news/2018/01/liquid-biopsy-promises-early-detection-cancer
Pro-apoptotic liposomes-nanobubble conjugate synergistic with paclitaxel: a platform for ultrasound responsive image-guided drug delivery.
Chandan R1, Banerjee R2.
Author information
Abstract
Recently, liposomes-microbubble conjugates have emerged as a promising ultrasound (US)-responsive platform for cancer therapeutics. However, these are limited by their size in terms of tumor penetration. Additionally, there have been no attempts to enhance the smartness of such conjugates which have been used only as passive carriers. The present study explores submicron sized (756?±?180.0?nm), US-responsive, phosphatidylserine (PS)-based paclitaxel-liposomes-nanobubble conjugates (PSPLBC) with an additional pro-apoptotic effect towards enhanced anti-cancer efficacy and image-guidance. The developed PSPLBC underwent cavitation in response to US-trigger, exhibiting in vitro pulsatile release with a 10-fold increase in cellular internalization as compared to control. The PS-containing formulations were found to be pro-apoptotic and exhibited strong synergism between PS and paclitaxel (Combination Index, CI?<?0.1). This resulted in significantly high anti-tumor efficacy both in vitro and in vivo conditions (98.3?±?0.8% tumor growth inhibition, TGI). Significant reduction in tumor proliferation index and MVD, as well as significant increase in apoptosis, were observed for the treated tumor sections. Further, the intravenous (i.v.) administration of PSPLBC enhanced the tumor US-contrast by 2-fold as compared to SonoVue. These results, show the potential of PSPLBC as a promising non-invasive, pro-apoptotic, smart DDS for US-responsive, image-guided cancer therapeutics.
https://www.ncbi.nlm.nih.gov/pubmed/29422676
A Novel Therapeutic Strategy for Cancer Using Phosphatidylserine Targeting Stearylamine-Bearing Cationic Liposomes
Manjarika De3, Sneha Ghosh3, Triparna Sen3,4, Md. Shadab5, Indranil Banerjee6, Santanu Basu, Nahid Ali'Correspondence information about the author Nahid AliEmail the author Nahid Ali
3These authors contributed equally to this work.
4Present address: Thoracic/Head & Neck Medical Oncology, Clinical Research Building, T8.3986, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
5Present address: Department of Dermatology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
6Present address: School of Medical Science & Technology, Indian Institute of Technology Kharagpur, Kharagpur 721302, India
Published Online: December 01, 2017
http://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(17)30283-4
From a Patient Advocate’s Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
https://link.springer.com/article/10.1007%2Fs11912-018-0662-5
Discovery of Phosphatidic Acid, Phosphatidylcholine, and Phosphatidylserine as Biomarkers for Early Diagnosis of Endometriosis.
Li J1, Gao Y2, Guan L2, Zhang H2, Sun J2, Gong X3, Li D2, Chen P4, Ma Z5, Liang X1, Huang M2, Bi H2.
Author information
Abstract
The sensitivity and specificity of clinical diagnostic indicators and non-invasive diagnostic methods for endometriosis at early stage is not optimal. Previous studies demonstrated that abnormal lipid metabolism was involved in the pathological development of endometriosis. Our cross-sectional study included 21 patients with laparoscopically confirmed endometriosis at stage I-II and 20 infertile women who underwent diagnostic laparoscopy combined with hysteroscopy from January 2014 to January 2015. Eutopic endometrium was collected by pipelle endometrial biopsy. Lipid metabolites were quantified by ultra-high performance liquid chromatography coupled with electrospray ionization high-resolution mass spectrometry (UHPLC-ESI-HRMS). Lipid profiles of endometriosis patients at early stage (I-II) was characterized by a decreased concentration of phosphatidylcholine (18:1/22:6), (20:1/14:1), (20:3/20:4), and phosphatidylserine (20:3/23:1) and an increased concentration of phosphatidic acid (25:5/22:6) compared with control. The synthesized predicting strategy with 5 biomarkers has a specificity of 75.0% and a sensitivity of 90.5%. Lipid profile of eutopic endometrium in endometriosis was effectively characterized by UHPLC-ESI-HRMS-based metabolomics. Our study demonstrated the alteration of phosphatidic acid, phosphatidylcholine, phosphatidylserine metabolites in endometriosis and provided potential biomarkers for semi-invasive diagnose of endometriosis at early stage.
https://www.ncbi.nlm.nih.gov/pubmed/29410629
https://doi.org/10.3389/fphys.2018.00014
Janus-Faced Myeloid-Derived Suppressor Cell Exosomes for the Good and the Bad in Cancer and Autoimmune Disease
Front. Immunol., 02 February 2018 | https://doi.org/10.3389/fimmu.2018.00137
Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment
https://www.sciencedirect.com/science/article/pii/S0168365918300464
Ebola virus requires a host scramblase for externalization of phosphatidylserine on the surface of viral particles
Published: January 16, 2018
Antitumor activity of HPA3P through RIPK3-dependent regulated necrotic cell death in colon cancer
http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=24083&path%5B%5D=75711
Dulling cancer therapy’s double-edged sword: A new way to block tumor recurrence
https://vector.childrenshospital.org/2018/01/resolvins-block-cancer-recurrence/
Hmmmm.......PS.....no value.......hahaha.......IMO
This is from October 2017!
Just to inform you.....
Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T
http://www.mdpi.com/1422-0067/19/2/340/htm
Old from 2010 but full with PS
Dendritic Cell Apoptosis: Regulation of Tolerance versus Immunity
http://www.jimmunol.org/content/185/2/795
Maybe they bought all Bavi.......
Anti-Human Phosphatidylserine Therapeutic Antibody (Bavituximab) from Creative Biolabs
https://www.biocompare.com/9776-Antibodies/8718097-Anti-Human-Phosphatidylserine-Therapeutic-Antibody-Bavituximab/?pda=9776|8718097_0_0|1529|18|Phosphatidylserine
Introduction by the Guest Editors: The PD-1 Axis in Cancer Therapy
Jedd D. Wolchok; Margaret K. Callahan
https://insights.ovid.com/pubmed?pmid=29360720
Avid Bioservices to Present at NobleCon14 - GNW
23-Jan-2018 14:05
TUSTIN, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a company working to improve patient lives by providing high quality biologics manufacturing services to biotechnology and pharmaceutical companies, today announced that its president and chief executive officer, Roger J. Lias, Ph.D., will deliver a corporate presentation at NobleCon14 - Noble Financial Capital Markets’ Fourteenth Annual Investor Conference, being held January 29-30, 2018 at the W Fort Lauderdale Beach Hotel in Fort Lauderdale, Florida.
Details of this presentation are as follows:
NobleCon14
Time/Date: 11:30 a.m. ET on Monday, January 29, 2018 Location: W Fort Lauderdale Beach Hotel Room: Studio 1
Avid’s presentation at NobleCon14 will be webcast live and available for replay at: http://ir.avidbio.com/events.cfm.
About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With nearly 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. www.avidbio.com
Contacts:
Kelly Pisarev Lord
Avid Bioservices, Inc.
(800) 987-8256
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
GlobeNewswire, Inc. 2018
A Cure for Cancer? How CAR-T Therapy is Revolutionizing Oncology
https://labiotech.eu/car-t-therapy-cancer-review/
A cationic, C-terminal patch and structural rearrangements in Ebola virus matrix VP40 protein control its interactions with phosphatidylserine.
Del Vecchio K1, Frick CT1, Gc JB2, Oda SI3, Gerstman BS2, Saphire EO3, Chapagain PP2, Stahelin RV4.
Author information
Abstract
Ebola virus (EBOV) is a filamentous lipid-enveloped virus that causes hemorrhagic fever with a high fatality rate. Viral protein 40 (VP40) is the major EBOV matrix protein and regulates viral budding from the plasma membrane. VP40 is a transformer/morpheein that can structurally rearrange its native homodimer into either a hexameric filament that facilitates viral budding or a RNA-binding octameric ring that regulates viral transcription. VP40 associates with plasma-membrane lipids such as phosphatidylserine (PS), and this association is critical to budding from the host cell. However, it is poorly understood how different VP40 structures interact with PS, what essential residues are involved in this association, and whether VP40 has true selectivity for PS among different glycerophospholipid headgroups. In this study, we used lipid-binding assays, MD simulations, and cellular imaging to investigate the molecular basis of VP40-PS interactions and to determine whether different VP40 structures (i.e. monomer, dimer, and octamer) can interact with PS-containing membranes. Results from quantitative analysis indicated that VP40 associates with PS vesicles via a cationic patch in the C-terminal domain (Lys-224, 225 and Lys-274, 275). Substitutions of these residues with alanine reduced PS-vesicle binding by >40-fold and abrogated VP40 localization to the plasma membrane. Dimeric VP40 had 2-fold greater affinity for PS-containing membranes than the monomer, whereas binding of the VP40 octameric ring was reduced by nearly 10-fold. Taken together, these results suggest the different VP40 structures known to form in the viral life cycle harbor different affinities for PS-containing membranes.
https://www.ncbi.nlm.nih.gov/pubmed/29348171
This is from Nov.2017
http://www.tandfonline.com/doi/full/10.1080/2162402X.2017.1385690
Novartis : Reports Summarize Cancer Study Results from Novartis (Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3...
01/19/2018 | 01:53am CET
Reports Summarize Cancer Study Results from Novartis (Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy)
By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Investigators publish new report on Oncology - Cancer. According to news reporting from Cambridge, Massachusetts, by NewsRx journalists, research stated, "Both data in preclinical cancer models and data with T cells from patients with advanced cancer support a role for Tim-3 blockade in promoting effective anti-tumor immunity. Consequently, there is considerable interest in the clinical development of antibody-based therapeutics that target Tim-3 for cancer immunotherapy."
The news correspondents obtained a quote from the research from Novartis, "A challenge to this clinical development is the fact that several ligands for Tim-3 have been identified: galectin-9, phosphatidylserine, HMGB1, and most recently, CEACAM1. These observations raise the important question of which of these multiple receptor:ligand relationships must be blocked by an anti-Tim-3 antibody in order to achieve therapeutic efficacy. Here, we have examined the properties of anti-murine and anti-human Tim-3 antibodies that have shown functional efficacy and find that all antibodies bind to Tim-3 in a manner that interferes with Tim-3 binding to both phosphatidylserine and CEACAM1."
According to the news reporters, the research concluded: "Our data have implications for the understanding of Tim-3 biology and for the screening of anti-Tim-3 antibody candidates that will have functional properties ."
For more information on this research see: Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy. Oncoimmunology, 2017;7(2):e1385690 (see also Oncology - Cancer).
Our news journalists report that additional information may be obtained by contacting C.A. Sabatos-Peyton, Exploratory Immuno-oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA, United States. Additional authors for this research include J. Nevin, A. Brock, J.D. Venable, D.J. Tan, N. Kassam, F. Xu, J. Taraszka, L. Wesemann, T. Pertel, N. Acharya, M. Klapholz, Y. Etminan, X. Jiang, Y.H. Huang, R.S. Blumberg, V.K. Kuchroo and A.C Anderson.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1080/2162402X.2017.1385690. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
Keywords for this news article include: Antibodies, Pharmaceutical Companies, Cancer, Business, Oncology, Cambridge, Immunology, Massachusetts, United States, Micronutrient, Blood Proteins, Immunoglobulins, Diet and Nutrition, Drugs and Therapies, Health and Medicine, North and Central America, Phosphatidylserine Therapy.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC
(c) 2018 NewsRx LLC, source Health Newsletters
http://www.4-traders.com/NOVARTIS-9364983/news/Novartis-Reports-Summarize-Cancer-Study-Results-from-Novartis-Blockade-of-Tim-3-binding-to-phosph-25834427/
Robust antitumor responses result from local chemotherapy and CTLA-4 blockade.
Ariyan CE1, Brady MS2, Siegelbaum RH3, Hu J2, Bello DM2, Green J2, Fisher C4, Lefkowitz RA5, Panageas KS6, Pulitzer M7, Vignali M8, Emerson R8, Tipton C8, Robins H8, Merghoub T9, Yuan J10, Jungbluth A7, Blando J11, Sharma P11, Rudensky AY11, Wolchok JD9, Allison JP11.
Author information
Abstract
Clinical responses to immunotherapy have been associated with augmentation of preexisting immune responses, manifested by heightened inflammation in the tumor microenvironment. However, many tumors have a non-inflamed microenvironment, and response rates to immunotherapy in melanoma have been <50%. We approached this problem by utilizing immunotherapy (CTLA-4 blockade) combined with chemotherapy to induce local inflammation. In murine models of melanoma and prostate cancer, the combination of chemotherapy and CTLA-4 blockade induced a shift in the cellular composition of the tumor microenvironment, with infiltrating CD8+ and CD4+ T cells increasing the CD8/Foxp3 T-cell ratio. These changes were associated with improved survival of the mice. To translate these findings to a clinical setting, 26 patients with advanced melanoma were treated locally by isolated limb infusion with the nitrogen mustard alkylating agent melphalan followed by systemic administration of CTLA-4 blocking antibody (ipilimumab) in a phase II trial. This combination of local chemotherapy with systemic checkpoint blockade inhibitor resulted in a response rate of 85% at 3 months (62% complete and 23% partial response rate), and a 58% progression-free survival at one year. The clinical response was associated with increased T-cell infiltration, similar to that seen in the murine models. Together, our findings suggest that local chemotherapy combined with checkpoint blockade-based immunotherapy results in a durable response to cancer therapy.
https://www.ncbi.nlm.nih.gov/pubmed/29339377
Ebola virus requires a host scramblase for externalization of phosphatidylserine on the surface of viral particles.
Nanbo A1, Maruyama J2, Imai M3, Ujie M3, Fujioka Y1, Nishide S1, Takada A2,4, Ohba Y1, Kawaoka Y3,5,6.
Author information
Abstract
Cell surface receptors for phosphatidylserine contribute to the entry of Ebola virus (EBOV) particles, indicating that the presence of phosphatidylserine in the envelope of EBOV is important for the internalization of EBOV particles. Phosphatidylserine is typically distributed in the inner layer of the plasma membrane in normal cells. Progeny virions bud from the plasma membrane of infected cells, suggesting that phosphatidylserine is likely flipped to the outer leaflet of the plasma membrane in infected cells for EBOV virions to acquire it. Currently, the intracellular dynamics of phosphatidylserine during EBOV infection are poorly understood. Here, we explored the role of XK-related protein (Xkr) 8, which is a scramblase responsible for exposure of phosphatidylserine in the plasma membrane of apoptotic cells, to understand its significance in phosphatidylserine-dependent entry of EBOV. We found that Xkr8 and transiently expressed EBOV glycoprotein GP often co-localized in intracellular vesicles and the plasma membrane. We also found that co-expression of GP and viral major matrix protein VP40 promoted incorporation of Xkr8 into ebolavirus-like particles (VLPs) and exposure of phosphatidylserine on their surface, although only a limited amount of phosphatidylserine was exposed on the surface of the cells expressing GP and/or VP40. Downregulating Xkr8 or blocking caspase-mediated Xkr8 activation did not affect VLP production, but they reduced the amount of phosphatidylserine on the VLPs and their uptake in recipient cells. Taken together, our findings indicate that Xkr8 is trafficked to budding sites via GP-containing vesicles, is incorporated into VLPs, and then promote the entry of the released EBOV to cells in a phosphatidylserine-dependent manner.
https://www.ncbi.nlm.nih.gov/pubmed/29338048
NEXT:
Celgene in talks to buy Juno Therapeutics -WSJ - Reuters News
16-Jan-2018 23:57:45
Updates stock price, adds background
Jan 16 (Reuters) - Celgene Corp CELG.O is in talks to buy Juno Therapeutics Inc JUNO.O, which is working on an experimental gene therapy drug to treat cancer, the Wall Street Journal reported on Tuesday, citing sources familiar with the matter.
Shares of Juno, which has a market value of $5.57 billion, were up 42 percent at $64.59 in extended trading.
Chimeric antigen receptor T-cell therapy, or CAR T, harnesses the body's own immune cells to recognize and attack malignant cells. Novartis NOVN.S received the first U.S. Food and Drug Administration approval for a CAR T drug last year.
Juno does not yet have any FDA approvals for its CAR T drugs, but it released promising data from early trials for a blood cancer treatment in November. (Full Story)
It has had previous setbacks in developing the treatments, and shut down development of one leukemia treatment due to severe neurotoxicity that led to five patient deaths. (Full Story)
Still, CAR T treatments are expected to be blockbusters for drugmakers, costing up to $500,000 and generating billions of dollars in sales.
Gilead Sciences Inc GILD.O bought Juno rival Kite Pharma Inc for nearly $12 billion late last year.
The WSJ report comes days after Celgene said it had agreed to acquire Impact Biomedicines for as much as $7 billion, subject to certain milestones associated with regulatory hurdles and sales performance. (Full Story)
Senior executives from some of the largest pharmaceutical manufacturers told Reuters last week that they expect the Trump administration's tax overhaul to accelerate major acquisitions by drugmakers in 2018 after a slow year for deals i
Phosphatidylserine-exposing blood and endothelial cells contribute to the hypercoagulable state in essential thrombocythemia patients.
Tong D1, Yu M1, Guo L1, Li T1, Li J2, Novakovic VA3, Dong Z2, Tian Y2, Kou J4, Bi Y2, Wang J5, Zhou J6, Shi J7,8.
Author information
Abstract
The mechanisms of thrombogenicity in essential thrombocythemia (ET) are complex and not well defined. Our objective was to explore whether phosphatidylserine (PS) exposure on blood cells and endothelial cells (ECs) can account for the increased thrombosis and distinct thrombotic risks among mutational subtypes in ET. Using flow cytometry and confocal microscopy, we found that the levels of PS-exposing erythrocytes, platelets, leukocytes, and serum-cultured ECs were significantly higher in each ET group [JAK2, CALR, and triple-negative (TN) (all P?<?0.001)] than those in controls. Among ET patients, those with JAK2 mutations showed higher levels of PS-positive erythrocytes, platelets, neutrophils, and serum-cultured ECs than TN patients or those with CALR mutations, which show similar levels. Coagulation function assays showed that higher levels of PS-positive blood cells and serum-cultured ECs led to markedly shortened coagulation time and dramatically increased levels of FXa, thrombin, and fibrin production. This procoagulant activity could be largely blocked by addition of lactadherin (approx. 70% inhibition). Confocal microscopy showed that the FVa/FXa complex and fibrin fibrils colocalized with PS on ET serum-cultured ECs. Additionally, we found a relationship between D-dimer, prothrombin fragment F1?+?2, and PS exposure. Our study reveals a previously unrecognized link between hypercoagulability and exposed PS on cells, which might also be associated with distinct thrombotic risks among mutational subtypes in ET. Thus, blocking PS-binding sites may represent a new therapeutic target for preventing thrombosis in ET.
https://www.ncbi.nlm.nih.gov/pubmed/29332224
Global T-Cell Immunotherapy Market for Cancer & Pipeline Analysis Report 2018 PR Newswire
DUBLIN, Jan. 16, 2018
DUBLIN, Jan. 16, 2018 /PRNewswire/ --
The "Global T-Cell Immunotherapy Market for Cancer & Pipeline Analysis " (https://www.researchandmarkets.com/research/5l256l/global_tcell...) report has been added to ResearchAndMarkets.com's offering.
According to GLOBOCAN, approximately 15.2 Million incidences of cancer were registered in 2015. This number is forecasted to reach an approximate value of 19.3 Million and 21.6 Million by 2025 and 2030, respectively.
According to report on "Global T-Cell Immunotherapy Market for Cancer & Pipeline Analysis", T-cell Immunotherapy is a rapidly expanding field of oncology. This therapy is intended to overcome the challenge of getting the right type of T-cell to the target tumor. It makes use of patients own immune cells to fight cancer. These immune cells are obtained from the patient and genetically engineered before their use for the treatment. Numerous researches are being performed across the globe to explore the potential of T-cell Immunotherapy for the treatment of different types of cancer. During these researches, T-cell Immunotherapies have demonstrated clinical successes on some accounts along with some critical issues on others. Overall, this therapy has emerged as one of the innovative and potent arm of the immunotherapeutic market.
Some of the conventional treatment options for the treatment of cancer are chemotherapy and radiation therapy. Even though these treatment options help in slowing down the progression of the disease, there is no option for the complete eradication of the disease. Moreover, these conventional therapies have numerous side-effects associated with them, such as hair loss, nausea and abnormal blood cell counts. These limitations and adverse effects of conventional therapies have therefore created a significant need for the treatment of cancer with therapies having lesser side effects and better efficacy. One such novel therapy is T-cell Immunotherapy which has shown great promise in the treatment of cancer even in the advanced stages.
The report provides an in-depth study on the current state of the T-Cell Immunotherapy industry. Recently, the USFDA approved two T-cell Immunotherapies for the treatment of cancer. The approved therapies belong to the class of CAR T-cell Immunotherapies. CAR T-cell therapies are the most researched type of therapy as they have shown exceptional results during clinical trials. The market for such T-cell Immunotherapies is forecasted to grow at an exponential rate owing to the high venture capitalist investments and increasing research related activities in this field.
Furthermore, the global and regional prevalence of major types of cancer for which T-cell Immunotherapy is used is highlighted in the report. These cancers include leukemia, lymphoma, melanoma, ovarian cancer, and bladder cancer amongst others. This will help the companies to gain knowledge regarding the target population for various immunotherapies globally, and at regional level. Moreover, an extensive analysis of the pipeline of T-cell Immunotherapies has been provided in the report. This analysis has been performed on the basis of phases, therapeutic indications, geographies, vectors used, technology types, and key players. This segment also covers the list of the key ongoing clinical trials along with their clinical phases by industry and research collaborations.
The last section of the report discusses about the key players, such as Novartis, Gilead Sciences and Juno Therapeutics among others, in the global T-cell Immunotherapy industry. A brief business overview and financial information about each of these players has been provided in the report. The product portfolio, product pipeline, recent developments and strength-weakness analysis of every player has also been presented to assist the investors in developing an understanding of the strategies of major players. In the end, the areas of opportunities for the growth of this industry have also been highlighted in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global T-cell Immunotherapy market.
Key Topics Covered:
1. Analyst View
2. Research Methodology
3. Introduction
4. Global T-Cell Immunotherapy Market for Cancer
5. Global CAR T-Cell Immunotherapy Market for Cancer
6. Commercialized CAR T-Cell Immunotherapies for Cancer 6.1 Kymriah
6.2 Yescarta
7. Major Therapeutic Areas for T-Cell Immunotherapies 7.1 Hematological Malignancies
7.1.1 Leukemia
7.1.2 Lymphoma
7.1.3 Multiple Myeloma
7.2 Solid Tumors
7.2.1 Melanoma
7.2.2 Bladder Cancer
7.2.3 Kidney Cancer
7.2.4 Ovarian Cancer
7.2.5 Breast Cancer
7.2.6 Lung Cancer
8. T-Cell Immunotherapy Pipeline Analysis 8.1 By Industry
8.1.1 By Vector
8.1.2 By Clinical Trial Phase
8.1.3 By Indication
8.1.4 By Technology
8.1.5 By Key Players
8.1.6 By Geography
8.2 By Research Collaborations
9. Market Opportunities
10. Key Player Analysis
10.1 Adaptimmune Therapeutics plc 10.2 Juno Therapeutics, Inc.
10.3 Gilead Sciences, Inc.
10.4 Novartis International AG
10.5 Tessa Therapeutics Pte Ltd. 10.6 Gradalis, Inc.
10.7 Immunovative Therapies, Ltd. 10.8 Iovance Biotherapeutics, Inc. (Formerly Lion Biotechnologies, Inc.) 10.9 Atara Biotherapeutics, Inc. 10.10 Celgene Corporation
10.11 Cellular Biomedicine Group 10.12 GlaxoSmithKline plc.
10.13 Immunocore Ltd.
10.14 Inovio Pharmaceuticals, Inc. 10.15 Cell Medica
For more information about this report visit https://www.researchandmarkets.com/research/5l256l/global_tcell...
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
The info for all:
Merck's Keytruda extends lung cancer survival in combination trial - Reuters News
16-Jan-2018 15:55:40
• Results cement Merck's lead in first-line lung cancer market
• Data increases chances of European approval - analyst
• Merck shares jump 6 percent
• Roche, Bristol-Myers, AstraZeneca fall
Adds analyst comment and background on first line treatments for lung cancer, updates share prices
By Tamara Mathias
Jan 16 (Reuters) - A cocktail of Merck & Co Inc's MRK.N blockbuster drug Keytruda and two chemotherapy medicines helped lung cancer patients live longer and stopped the disease from advancing, early results from a key study showed on Tuesday.
Merck's shares rose 6.2 percent to $62.29 after data from the late-stage study.
The results cement Merck's position as a front-runner in the race to develop drugs that can be used as the initial or first-line treatment for patients with a common type of lung cancer.
Swiss drugmaker Roche ROG.S, Merck's U.S. rival Bristol-Myers Squibb Co BMY.N and AstraZeneca Plc AZN.L are all developing combination lung cancer treatments of their own.
Merck has already secured U.S. regulatory approval for its combination based on positive results from an earlier trial.
But it withdrew a European marketing application for the combination last year after regulators asked for more data, disappointing some Merck investors.
The latest results increase the chances of a European regulatory approval, an analyst at Evercore ISI said.
"While this announcement puts Merck back on track, the final competitive landscape in first-line lung cancer is still far from resolved," said Alistair Campbell, an analyst at Berenberg.
Lung cancer is a lucrative oncology market and a first-line approval makes a drug available to the most patients.
Keytruda brought Merck more than $1 billion in sales in the third quarter and analysts expect the drug to generate peak sales of about $8.2 billion by 2020.
But Merck will have to rely heavily on Keytruda being used as a first-line lung cancer treatment to achieve that milestone, analysts said.
Roche's shares fell 3.4 percent, while shares of Bristol-Myers and AstraZeneca dipped between 1 and 3 percent.
Roche said last month its immunotherapy Tecentriq, when combined with other drugs, doubled the percentage of lung cancer patients who survived a year without their disease advancing.
(Full Story)
Merck's cocktail comprised Keytruda, Eli Lilly's LLY.N Alimta and a standard chemotherapy and was tested on patients with a type of non-small-cell lung cancer. (Full Story)
(Reporting by Tamara Mathias in Bengaluru; editing by Sai Sachin Ravikumar)